China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received fast-track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy, 177Lu-LNC1004, in patients with metastatic iodine-131 refractory differentiated thyroid cancer who have previously undergone treatment with at least one tyrosine kinase inhibitor.
177Lu-LNC1004 is a radiotherapeutic agent specifically designed to target fibroblast activation protein (FAP) and is being developed for the treatment of FAP-positive advanced solid tumors. Notably, there are currently no comparable products approved globally. The drug has already entered Phase I clinical trials in China, the U.S., and Singapore.- Flcube.com
